Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Awareness and preferences regarding BRCA1/2 genetic counseling and testing among Latinas and non-Latina white women at increased risk for hereditary breast and ovarian cancer.

Gammon AD, Rothwell E, Simmons R, Lowery JT, Ballinger L, Hill DA, Boucher KM, Kinney AY.

J Genet Couns. 2011 Dec;20(6):625-38. doi: 10.1007/s10897-011-9376-7.

PMID:
21691939
2.

Comparison of Latina and non-Latina white women's beliefs about communicating genetic cancer risk to relatives.

MacDonald DJ, Sarna L, Giger JN, Van Servellen G, Bastani R, Weitzel JN.

J Health Commun. 2008 Jul-Aug;13(5):465-79. doi: 10.1080/10810730802198920.

PMID:
18661388
3.

Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.

Forman AD, Hall MJ.

Breast J. 2009 Sep-Oct;15 Suppl 1:S56-62. doi: 10.1111/j.1524-4741.2009.00798.x. Review.

PMID:
19775331
4.

BRCA1 and BRCA2 risk perceptions among African American women at increased risk for hereditary breast-ovarian cancer.

Kessler L, Domchek S, Stopfer J, Halbert CH.

Community Genet. 2008;11(4):193-200. doi: 10.1159/000116879.

PMID:
18417966
5.

Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women.

Thompson HS, Valdimarsdottir HB, Duteau-Buck C, Guevarra J, Bovbjerg DH, Richmond-Avellaneda C, Amarel D, Godfrey D, Brown K, Offit K.

Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1579-85.

6.

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.

Morgan D, Sylvester H, Lucas FL, Miesfeldt S.

Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z.

PMID:
19347608
7.

Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.

Lerman C, Biesecker B, Benkendorf JL, Kerner J, Gomez-Caminero A, Hughes C, Reed MM.

J Natl Cancer Inst. 1997 Jan 15;89(2):148-57.

PMID:
8998184
8.

Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.

Armstrong K, Micco E, Carney A, Stopfer J, Putt M.

JAMA. 2005 Apr 13;293(14):1729-36.

PMID:
15827311
9.

Counseling the at risk patient in the BRCA1 and BRCA2 Era.

Barnes-Kedar IM, Plon SE.

Obstet Gynecol Clin North Am. 2002 Jun;29(2):341-66, vii. Review.

PMID:
12108833
10.
11.

Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.

Di Prospero LS, Seminsky M, Honeyford J, Doan B, Franssen E, Meschino W, Chart P, Warner E.

CMAJ. 2001 Apr 3;164(7):1005-9.

12.

BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.

McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP.

Am J Med Genet A. 2004 Oct 15;130A(3):221-7.

PMID:
15378542
13.

Factors associated with decisions about clinical BRCA1/2 testing.

Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B.

Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1251-4.

14.

The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.

Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436.

15.

A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing.

Lehmann LS, Weeks JC, Klar N, Garber JE.

Genet Med. 2002 Sep-Oct;4(5):346-52.

PMID:
12394347
16.

An exploration of the communication preferences regarding genetic testing in individuals from families with identified breast/ovarian cancer mutations.

Ratnayake P, Wakefield CE, Meiser B, Suthers G, Price MA, Duffy J; Kathleen Cuningham National Consortium for Research into Familial Breast Cancer., Tucker K.

Fam Cancer. 2011 Mar;10(1):97-105. doi: 10.1007/s10689-010-9383-0.

PMID:
20878485
17.

BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.

McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP.

Am J Med Genet A. 2005 Mar 1;133A(2):165-9.

PMID:
15633195
18.

Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.

Finch A, Metcalfe K, Lui J, Springate C, Demsky R, Armel S, Rosen B, Murphy J, Elit L, Sun P, Narod S.

Clin Genet. 2009 Mar;75(3):220-4.

PMID:
19263514
19.

Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.

DiCastro M, Frydman M, Friedman I, Shiri-Sverdlov R, Papa MZ, Goldman B, Friedman E.

Am J Med Genet. 2002 Aug 1;111(2):147-51.

PMID:
12210341
20.

Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred.

Kinney AY, Simonsen SE, Baty BJ, Mandal D, Neuhausen SL, Seggar K, Holubkov R, Bloor L, Smith K.

J Genet Couns. 2006 Aug;15(4):293-305.

PMID:
16865561
Items per page

Supplemental Content

Support Center